TARGET-LOAD Pilot Study Comparing Hemodynamics-guided LVAD Unloading vs. Standard of Care
Heart Failure
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria:
- Severe clinical HF resistant to intensive medical therapy and requiring LVAD implantation
- Left ventricular ejection fraction <=25% and cardiomegaly at time of LVAD implantation
- Non-ischemic etiology of HF
- Undergone LVAD implantation within prior 4 weeks or planned for LVAD implant
- History of HF < 5 years
- Body Mass Index <=35 kg/m^2
- Pulmonary artery branch diameter between 7 - 15 mm
- Female subjects of childbearing age with negative urine or serum pregnancy test and agreeing to use reliable mechanical or hormonal form of contraception during study
Exclusion Criteria:
- Evidence of active acute myocarditis confirmed by histology
- History of previous cerebrovascular accident resulting in significant fixed motor deficit, limiting ability to perform exercise testing
- Implanted mechanical aortic and/or mitral valve(s) and/or right heart valve(s)
- Aortic valve closure
- Hypertrophic obstructive cardiomyopathy or sarcoidosis
- Left ventricular end-diastolic diameter below normal (restrictive cardiomyopathy)
- Irreversible multi-organ failure
- Diagnosis of psychiatric disease, irreversible cognitive dysfunction or poor psycho-social issues likely to impair compliance with study protocol
- Any condition that could limit survival to less than 2 years
- History of cardiac or other organ transplant
- Contraindicated to anti-coagulation, antiplatelet therapy, or diagnosis of coagulation disorders
- Require acute or chronic renal replacement therapy within 3 months prior to enrollment
- Participation in any other clinical investigations involving another Mechanical Circulating Support device or HF-related drug
- Active infection
- History of recurrent (>1) pulmonary embolism or deep vein thrombosis
- Unable to tolerate right heart catheterization
- Implantation of cardiac re-synchronization therapy < 3 months before enrollment
- Congenital heart disease
- Hypersensitivity or allergy to aspirin and/or clopidogrel
Sites / Locations
- University of Kentucky
- Inova Heart and Vascular Institute
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control
Intervention
After LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.
After LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.